IL0011809592 - Common Stock - After market: 1.58 -0.05 (-3.07%)
NASDAQ:NRSN (2/3/2023, 7:00:03 PM)-0.02 (-1.21%)
GICS Sector | Health Care | ||
GICS Industry | Biotechnology |
Valuation | Growth | ||
Profitability | Health | ||
Dividend |
Earnings (Last) | 08-31 2022-08-31/bmo | Earnings (Next) | 12-13 2022-12-13/bmo |
Ins Owners | N/A | Inst Owners | N/A |
Market Cap | 19.03M | Shares | 11.67M |
PE | N/A | Fwd PE | N/A |
Dividend Yield | N/A | Analysts | 82.86 |
IPO | 12-09 2021-12-09 |
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company. The firm is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The firm's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease
NEUROSENSE THERAPEUTICS LTD
11 Hamenofim St., Building B
Herzliya
P: 97299531142.0
Employees: 11
Website: https://www.neurosense-tx.com/
It's the final day of trading this week and we're checking in on the biggest pre-market stock movers for Friday morning!
NeuroSense (NRSN) stock is taking off on Thursday as investors react to data from a biomarker study concerning Alzheimer's disease (AD).
Microcap NeuroSense Therapeutics (NRSN) is up 92% in Thursday morning trading after the reporting positive results for a biomarker study of its combination platform therapy for Alzheimer's.
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today...
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today...
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today...
Here you can normally see the latest stock twits on NRSN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: